Compare Quanta Services Inc (PWR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Quanta Services Inc trades at $627 (market cap $96.08B), while Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B). The key difference: Quanta Services Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.46%). Which is the better fit depends on your goals.
| PWR | REGN | |
|---|---|---|
Market Cap | $96.08B | $83.43B |
Sector | Industrials | Health |
52-Week High | $785.24 | $852.03 |
52-Week Low | $376.01 | $555.51 |
Enterprise Value | $102.17B | $78.14B |
Dividend Yield | 0.07% | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quanta Services (PWR) trades at $639.05, up 2.34% with strong technical momentum and bullish sentiment. The stock shows robust fundamentals with revenue growth from $17.1B in 2022 to $28.5B in 2025, supported by a record $53B backlog. Recent Q2 2026 earnings beat expectations with EPS of $4.24 versus $3.31 expected, while analyst consensus remains strongly bullish with a $811.14 price target.
PWR presents compelling growth potential driven by infrastructure demand and AI-related projects, though elevated valuation multiples (P/E 73.12) and significant capital expenditures pose risks. The company's strong backlog and margin expansion support upside, but investors should monitor execution on large-scale projects and competitive pressures in the construction sector.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
